Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has received approval from the Ethics Committee regarding its first clinical trial for SCO-101 at hospitals in Denmark. The only change that the Ethics Committee requested was to include a one-page summary of the patient information sheet for review before the study could be started. With this approval, Scandion Oncology follows its objectives.
Clinical Phase II trial with SCO-101 in patients with drug-resistant metastatic colorectal cancer
Scandion Oncology’s first clinical Phase II study with SCO-101 targeting chemotherapy resistance in patients with drug-resistant metastatic colorectal cancer will start at Herlev Hospital, Copenhagen. Screening for eligible patients will be initiated shortly, and according to the clinical investigators, there will be many eligible patients that can be screened for inclusion in the trial as most patients with metastatic colorectal cancer who receive chemotherapy treatment will at some point present with drug resistant disease.
CEO Nils Brünner comments
“With this approval from the Ethics Committee, we will soon be ready to treat drug-resistant metastatic colorectal cancer patients by combining SCO-101 with chemotherapy. I look forward to initiating the study and I am pleased that we continue to follow our set goals regarding our first Phase II clinical trial with SCO-101 in patients with metastatic colorectal cancer.” However, most importantly, with positive data from this study the journey can continue and ultimately prolong survival or even save the life of future cancer patients who otherwise would have lost the fight against cancer due to drug resistance.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on December 23 2019.
Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and targeting one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.